1
|
Thomas F, Abiri OT, Kallon JM, Kangbai DM, Conteh TA, Conteh SM, Samuels EG, Awodele O. Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone. Drug Healthc Patient Saf 2024; 16:61-73. [PMID: 38911456 PMCID: PMC11193982 DOI: 10.2147/dhps.s466039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Accepted: 06/11/2024] [Indexed: 06/25/2024] Open
Abstract
Background The manifestation and spread of neuroinvasive circulating vaccine-derived polioviruses (cVDPVs) across several countries, which led to the emergency use of the novel oral polio vaccine type 2 (nOPV2), raised concerns about adverse events following immunization (AEFI) surveillance. We assessed the attributes of AEFI with nOPV2 and examined stakeholder experiences and challenges in AEFI surveillance in Sierra Leone. Methods Using a mixed method approach, we retrospectively reviewed passive data collected during a 2021 immunization campaign, and conducted semi-structured, interviews with vaccinators, district AEFI focal persons, and key stakeholders at the national Expanded Program on Immunization and the National Medicines Regulatory Authority. AEFI were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) and System Organ Class (SOC). Outcomes were stratified as recovered or not, with preventability and causality assessed using the Schumock and Thornton and World Health Organization (WHO) algorithms, respectively. Results A total of 528 suspected AEFI were documented, predominantly affecting children aged 28 days to 23 months (63.3%). Most reported AEFI were administration site conditions and general disorders, with pyrexia being the predominant PT. Of 80 serious cases, 78 recovered, with 74 having an inconsistent causal relationship with the vaccine. Most serious cases (78) were deemed non-preventable, with only two being probably preventable. AEFI reporting was not routinely carried out across the group of people interviewed. AEFI reporting was not consistently performed, with discrepancies in defining reportable events and confusion over responsibility. Challenges with the open data kit (ODK) platform were noted, along with perceived inadequacies in training. Conclusion While the nOPV2 is relatively new, the majority of AEFI were not serious, and most serious cases were not causally linked to the vaccine. Participants exhibited variations in experience and awareness of AEFI reporting.
Collapse
Affiliation(s)
- Fawzi Thomas
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
- Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone
| | - Onome T Abiri
- Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone
- Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Joyce M Kallon
- Expanded Program on Immunization, Freetown, Sierra Leone
| | | | - Thomas A Conteh
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
- Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone
| | | | - Edna G Samuels
- Expanded Program on Immunization, Freetown, Sierra Leone
| | - Olufunsho Awodele
- Department of Pharmacology, Therapeutics and Toxicology, College of Medicine, University of Lagos, Lagos, Nigeria
| |
Collapse
|
2
|
Azees AS, Fasiku MM, Isa A, Ezenwoko AZ, Ahmed A, Temitayo-Oboh AO, Utulu R, Adeniyi MA, Musa A, Alo C, Ibrahim UM, Imhonopi GB, Adesoye OO, Okeke IM, John GT, Ayinla AY. Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria. Niger Postgrad Med J 2024; 31:1-7. [PMID: 38321791 DOI: 10.4103/npmj.npmj_227_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 01/22/2024] [Indexed: 02/08/2024]
Abstract
BACKGROUND Vaccines, including COVID-19 vaccines, are known to be cost-effective interventions for disease prevention and control. However, adverse events following immunisation (AEFI) may challenge the acceptance of these vaccines. This study assessed the prevalence and severity of COVID-19-related AEFI amongst healthcare workers at tertiary health facilities in Nigeria. MATERIALS AND METHODS This descriptive, cross-sectional study was conducted among healthcare workers who had received the COVID-19 vaccine. A multi-stage sampling technique was used to select participants from six Tertiary Health Facilities in Nigeria. Ethical approval (NHREC/01/01/2007-19/07/2021) was obtained from NHREC. Data were analysed using IBM® SPSS version 25 and categorical variables were presented in tables/charts using frequencies and proportions. RESULTS A total of 2130 respondents participated in the study, with a mean age of 37.4 ± 9.1 years. Most of the respondents, 1674 (78.6%), had two doses of the vaccine, and the overall prevalence of AEFI was 813 (38.2%). Common among the AEFI reported following the administration of the first dose of the vaccine were fever 649 (30.5%) and pain at the injection site 644 (30.2%), while it was pain at the injection site 216 (10.1%) and fever 173 (8.1%) for second dose. The higher proportions of AEFI were mostly mild to moderate. CONCLUSION The study observed a relatively low prevalence of AEFI, with the commonly reported ones being fever and injection site pain. It is crucial that countries continuously collect the data on AEFI and establish causality as a way to improve quality and guarantee vaccine safety.
Collapse
Affiliation(s)
- Ayotunde Sherif Azees
- Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria
| | - Mojirola Martina Fasiku
- Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria
| | - Abdulfattah Isa
- Department of Public Health, Federal Medical Centre, Birnin Kebbi, Nigeria
| | - Ahuna Zainab Ezenwoko
- Department of Community Medicine, Usmanu Danfodiyo University Teaching Hospital, Argungu, Kebbi State, Nigeria
| | - Abdullahi Ahmed
- Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria
| | | | - Rowland Utulu
- Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria
| | - Makinde Adebayo Adeniyi
- Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria
| | - Abubakar Musa
- Department of Community Medicine, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria
| | - Chihurumnanya Alo
- Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria
| | - Usman Muhammed Ibrahim
- Department of Community Medicine, Federal University Dutse, Dutse, Jigawa State, Nigeria
| | - Gloria Bosede Imhonopi
- Department of Community Medicine and Primary Care, Federal Medical Center, Abeokuta, Ogun State, Nigeria
| | - Oluwaseun Opeyemi Adesoye
- Department of Community Medicine, Medicine Delta State University Teaching Hospital, Oghara, Nigeria
| | - Ifeyinwa Maureen Okeke
- Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria
| | - Godwin ThankGod John
- Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria
| | - Abdulquadri Yeketi Ayinla
- Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Nigeria
| |
Collapse
|
3
|
Hu R, Liu Y, Zhang L, Kang G, Xu B, Li M, Yu J, Zhu Y, Guo H, Wang Z. Post-marketing safety surveillance for both CRM197 and TT carrier proteins PCV13 in Jiangsu, China. Front Public Health 2023; 11:1272562. [PMID: 37908689 PMCID: PMC10613985 DOI: 10.3389/fpubh.2023.1272562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 09/28/2023] [Indexed: 11/02/2023] Open
Abstract
Background This study is to evaluate the safety of two kinds of PCV13 carriers by monitoring the occurrence of adverse event following immunization (AEFI) after the launch of two kinds of PCV13 carriers in Jiangsu Province, China. Methods The AEFI Information System (CNAEFIS) of mainland China was used to monitor the incidence and classification of adverse reactions of the CRM197-carrier protein PCV13 and TT-carrier protein PCV13 vaccines. Results There was no statistical difference between the cumulative reported incidence of AEFI between the two vaccines from 2020 to 2022 (χ2 = 1.991, p < 0.158). 96.62% of the AEFIs were classified as common reactions; rare reactions and coincidental events only accounted for 2.99 and 0.39% of all the AEFI cases, respectively. Redness (2.6 cm-5 cm) is the commonest symptom at the injection site for both vaccines. More than 97% of AEFIs occurred between 30 min and 3 days after administration for both types of PCV13. Conclusion Both vaccines perform well in terms of safety. We did not identify any new/unexpected safety concern from the NAEFISS during a 4 years timespan.
Collapse
Affiliation(s)
- Ran Hu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Yuanbao Liu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Lei Zhang
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Guodong Kang
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Borong Xu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Mingma Li
- Department of Epidemiology and Health Statistics, Southeast University School of Public Health, Nanjing, China
| | - Jing Yu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Yuanyuan Zhu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Hongxiong Guo
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Zhiguo Wang
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| |
Collapse
|
4
|
Kara A, Coskun A, Temel F, Özelci P, Topal S, Ates İ. Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population. Vaccines (Basel) 2023; 11:vaccines11020437. [PMID: 36851314 PMCID: PMC9958953 DOI: 10.3390/vaccines11020437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 02/01/2023] [Accepted: 02/07/2023] [Indexed: 02/17/2023] Open
Abstract
TURKOVAC™ is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in Türkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administration of the vaccine as the primary or the booster dose in 15 provinces in Türkiye. In this cohort study, between February and May 2022, in the selected 15 provinces having an adequate number of health care personnel in the community health centers to conduct the study, 32,300 people having the first, the second, or the booster dose of the vaccine were invited to the survey. A total of 29,584 people voluntarily agreed to participate to the survey and were given a structured questionnaire after a minimum of 10 days following the vaccination. In our study, only 0.5% of the participants (142 persons) reported to experience any allergic reaction, and 12 of them (8.5%) reported to be given medical treatment in a health center. Male predominance (55.6%) was observed among participants reported to experience any allergic reaction. No hospitalization was recorded. Of the participants, 4.4% (1315 people) reported to have a history of allergy. The most reported allergens were drugs. Among the participants without a known history of allergy (n = 28,269), 0.4% of them (110 people) reported to experience an allergic reaction following the vaccination, and 5.4% of the allergic reactions (six people) were reported to be treated in a health center. The percentage of the participants given any medical treatment among the participants without a known history of allergy is 0.02%. No immediate or anaphylactic reaction was reported. Among the participants with a known history of allergy (n = 1315), 32 people (2.4% of them) reported to experience an allergic reaction following the vaccination, and 18.7% of the allergic reactions (six people) were reported to be prescribed a medical treatment. The percentage of the participants given any medical treatment among the participants with a known history of allergy is 0.4%. A known history of allergy increased the risk of having an allergic experience by approximately six times following vaccination. As a whole-virion inactivated SARS-CoV-2 vaccine, the TURKOVAC™ vaccine, with a low allergic reaction-related adverse event profile, can be an alternative to other COVID-19 vaccines.
Collapse
Affiliation(s)
- Ateş Kara
- Department of Pediatrics, Pediatric Infectious Disease Unit, Hacettepe University Faculty of Medicine, Health Institutes of Türkiye, Türkiye Vaccine Institute, Ankara 06100, Türkiye
- Correspondence:
| | - Aslihan Coskun
- Health Institutes of Türkiye, Türkiye Vaccine Institute, Ankara 06260, Türkiye
| | - Fehminaz Temel
- Türkiye Ministry of Health, General Directorate of Public Health, Department of Communicable Diseases and Early Warning, Field Epidemiology Unit, Ankara 06430, Türkiye
| | - Pervin Özelci
- Health Institutes of Türkiye, Türkiye Vaccine Institute, Ankara 06260, Türkiye
| | - Selmur Topal
- Türkiye Ministry of Health, General Directorate of Public Health, Department of Communicable Diseases and Early Warning, Field Epidemiology Unit, Ankara 06430, Türkiye
| | - İhsan Ates
- University of Health Science, Ankara City Hospital, Department of Internal Medicine, Ankara 06610, Türkiye
| |
Collapse
|
5
|
Asfaw M, Senbit M, Yesuf M, Dagnaw M, Birhan G, Abat AS, Ibrahim SM. A Preliminary Investigation on a Commercial Ovine Pasteurellosis Vaccine Using Clinical and Pathological Endpoints. Infect Drug Resist 2022; 15:2937-2948. [PMID: 35706927 PMCID: PMC9189154 DOI: 10.2147/idr.s365745] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 05/27/2022] [Indexed: 11/23/2022] Open
Abstract
Introduction In this study we aimed to provide preliminary evidence on the safety and efficacy of the currently used ovine pasteurellosis vaccine in Ethiopia using clinical and pathological endpoints. Methods Twenty, conventionally reared, apparently healthy, seronegative male lambs, were randomly classified into two groups of 10 animals as "vaccinated-challenged" and "unvaccinated-challenged controls". The first group received 1 mL of the licensed Pasteurella multocida biotype A based vaccine subcutaneously while the second group received phosphate-buffered saline as a placebo. Following vaccination, lambs were monitored for one month for potential vaccine adverse reactions. Five weeks postvaccination, all lambs were immunosuppressed using dexamethasone, and intratracheally challenged with 5.2×109 CFU/mL live Mannheimia haemolytica A1 (clinical isolates). Then, all lambs were followed up for eight days for clinical examination and necropsied on the ninth day postchallenge for pathological investigation. Results There were no safety issues recorded during the study. In terms of clinical signs, lambs developed fever, depression, mucoid bilateral oculonasal discharge, coughing and sneezing regardless of their vaccination status. Fisher's exact test between vaccination status and each clinical sign showed a statistically insignificant association (p>0.05). The main pathological findings in both groups were pulmonary congestion, atelectasis, emphysema, and suppurative bronchopneumonia. Consolidation lung lesion score of +1 (5/10 of vaccinated, 6/10 of unvaccinated) and +2 (3/10 of vaccinated, 4/10 of unvaccinated) were recorded in a statistically indifferent manner among both vaccinated and nonvaccinated groups (p>0.05). Discussion and Conclusion Collectively, the results suggested that the vaccine posed no safety concern and presumably lacks protective efficacy against local isolates. However, the study did not analyze antibody titer and their functionality using serum bactericidal assays. Further confirmatory studies could provide more evidence on the vaccine efficacy. Safety should further be assessed in a field setting involving a large number of animals to enable detection of rare vaccine adverse events.
Collapse
Affiliation(s)
- Mersha Asfaw
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Menur Senbit
- Department of Veterinary Epidemiology and Public Health, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Mohammed Yesuf
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Melkie Dagnaw
- Department of Veterinary Clinical Studies, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Girma Birhan
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Anmaw Shite Abat
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| | - Saddam Mohammed Ibrahim
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Animal Sciences, University of Gondar, Gondar, Ethiopia
| |
Collapse
|
6
|
Batista ECC, Ferreira AP, Alexandre BGP, Lima MRDS, Oliveira VC, Guimarães EADA. The influence of nursing team’s behavior in adverse event following immunization surveillance. Rev Bras Enferm 2022; 75:e20210132. [DOI: 10.1590/0034-7167-2021-0132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Accepted: 09/22/2021] [Indexed: 11/22/2022] Open
Abstract
ABSTRACT Objectives: to analyze the effects of nursing professionals’ behavior in adverse event following immunization surveillance. Methods: a cross-sectional study of 384 participants who received vaccines. Information on vaccination history, administered vaccines and vaccination guidelines were analyzed. Descriptive and bivariate analyzes were performed using simple logistic regression (unadjusted Odds Ratio). Results: guidelines on events (PR=1.8; p=0.001) and conducts regarding their occurrence (PR=1.7; p=0.001) are activities that influence adverse event following immunization surveillance. More than half of participants did not receive guidance on the vaccines administered, the events and the conduct in case of an occurrence. Only 38.5% were instructed about the vaccines administered and 40.6% about adverse events. In the presence of an event, 29.9% reported that they sought services for notification. Conclusions: proper screening, providing guidance on vaccines and adverse events are essential preventive measures to strengthen adverse event following immunization surveillance.
Collapse
|
7
|
Jin J, Zhang C, Guo X, Zhang L, Mei K, Zhou B, Lu J, Lu Y. Vaccination experiences of premature children in a retrospective hospital-based cohort in a Chinese metropolitan area. Hum Vaccin Immunother 2021; 17:5235-5241. [PMID: 34736371 DOI: 10.1080/21645515.2021.1989924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
BACKGROUND In China, premature children in good health may be advised to receive routine immunization programs. However, delayed vaccination is common. This study aimed to characterize vaccination experiences of premature children and determine the impact of vaccination consultation clinic (VCC) assessment. METHODS We performed a retrospective cohort study, including premature children visiting VCC at Children's Hospital of Fudan University in 2017-2019. Data of these children, including demographics, recommendations of vaccination after VCC assessment, vaccination records, adverse events following immunization (AEFI), and incidence of vaccine-preventable diseases in 2017-2019, were collected retrospectively. RESULTS A total of 1124 premature children were included, with vaccination uptake of 46.3% for expanded program of immunization (EPI) vaccines and 15.1% for non-EPI vaccines before VCC assessment. Furthermore, 77.5% of premature children who had not received any EPI vaccine were vaccinated after the assessment; however, most were delayed, regardless of vaccine types and recommendations. In contrast, 67.3% was vaccinated with non-EPI vaccines after the assessment. Majority (n = 35) of recorded AEFI was mild to moderate, in addition to one allergic rash. One each case of pertussis and varicella were recorded in those who had not received the corresponding vaccines. CONCLUSION Vaccination may be safe and epidemiological effective in premature children. However, it remains mostly delayed in premature children with recommendations of normal vaccination. It warrants improving implementation of VCC recommendations. In addition, there is a need of health promotion on more non-EPI vaccines for premature children.
Collapse
Affiliation(s)
- Jie Jin
- Vaccination Consultation Clinic, Children's Hospital of Fudan University, Shanghai, China
| | - Chengjun Zhang
- Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public, Fudan University, Shanghai, China
| | - Xiang Guo
- Institute of Immunization, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China
| | - Liping Zhang
- Department of Immunization, Minhang District Center for Disease Control and Prevention, Shanghai, China
| | - Kewen Mei
- Department of Immunization, Minhang District Center for Disease Control and Prevention, Shanghai, China
| | - Beihua Zhou
- Vaccination Consultation Clinic, Children's Hospital of Fudan University, Shanghai, China
| | - Jia Lu
- Department of Immunization, Minhang District Center for Disease Control and Prevention, Shanghai, China
| | - Yihan Lu
- Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, School of Public, Fudan University, Shanghai, China
| |
Collapse
|